» Articles » PMID: 39062871

Microvascular Dysfunction Across the Spectrum of Heart Failure Pathology: Pathophysiology, Clinical Features and Therapeutic Implications

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Jul 27
PMID 39062871
Authors
Affiliations
Soon will be listed here.
Abstract

Coronary microvascular dysfunction (CMD) plays a crucial role across the spectrum of heart failure (HF) pathology, contributing to disease development, progression, and outcomes. The pathophysiological mechanisms linking CMD to HF are complex and still not completely understood and include chronic inflammation, oxidative stress, and neurohormonal activation. Despite the diagnostic and prognostic relevance in patients with HF, there is no specific therapeutic strategy targeting CMD to date. Moreover, the diagnosis of this clinical condition is challenging. In this review article, we aim to discuss the different clinical pathogenetic mechanisms linking CMD to HF across the different spectra of these diseases, their prognostic relevance, and the possible therapeutic targets along with the remaining knowledge gaps in the field.

Citing Articles

The Role of Circulating Biomarkers in Patients with Coronary Microvascular Disease.

Quarta R, Martino G, Romano L, Lopes G, Greco F, Spaccarotella C Biomolecules. 2025; 15(2).

PMID: 40001480 PMC: 11853534. DOI: 10.3390/biom15020177.


Acclimation of Hairless Spontaneously Hypertensive Rat to Ambient Temperature Attenuates Hypertension-Induced Pro-Arrhythmic Downregulation of Cx43 in the Left Heart Ventricle of Males.

Andelova K, Sykora M, Farkasova V, Stankovicova T, Szeiffova Bacova B, Knezl V Biomolecules. 2025; 14(12.

PMID: 39766216 PMC: 11674011. DOI: 10.3390/biom14121509.

References
1.
Yang J, Obokata M, Reddy Y, Redfield M, Lerman A, Borlaug B . Endothelium-dependent and independent coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. Eur J Heart Fail. 2019; 22(3):432-441. DOI: 10.1002/ejhf.1671. View

2.
Kato S, Fukui K, Kodama S, Azuma M, Nakayama N, Iwasawa T . Cardiovascular magnetic resonance assessment of coronary flow reserve improves risk stratification in heart failure with preserved ejection fraction. J Cardiovasc Magn Reson. 2021; 23(1):112. PMC: 8522041. DOI: 10.1186/s12968-021-00807-3. View

3.
Del Olmo-Garcia M, Merino-Torres J . GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes. J Diabetes Res. 2018; 2018:4020492. PMC: 5902002. DOI: 10.1155/2018/4020492. View

4.
Aspromonte N, Zaninotto M, Aimo A, Fumarulo I, Plebani M, Clerico A . Measurement of Cardiac-Specific Biomarkers in the Emergency Department: New Insight in Risk Evaluation. Int J Mol Sci. 2023; 24(21). PMC: 10648028. DOI: 10.3390/ijms242115998. View

5.
Lommi J, Pulkki K, Koskinen P, Naveri H, Leinonen H, HARKONEN M . Haemodynamic, neuroendocrine and metabolic correlates of circulating cytokine concentrations in congestive heart failure. Eur Heart J. 1997; 18(10):1620-5. DOI: 10.1093/oxfordjournals.eurheartj.a015142. View